SUBSCRIBE
SUBSCRIBE

ARB Cancer Risk for Hypertension Under FDA Review

July 16, 2010 | 
1 min read
One month after a meta-analysis suggested angiotensin receptor blockers (ARBs) for hypertension may increase cancer risk, the FDA has announced a formal safety review.